<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Manipulation of inhaled gases during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion is a potential novel therapy for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We previously found that treatment with a mixture of 70%/30% <z:chebi fb="64" ids="30217">helium</z:chebi>/oxygen (heliox) or 100% oxygen protects the brain against <z:hpo ids='HP_0011009'>acute</z:hpo> focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury </plain></SENT>
<SENT sid="2" pm="."><plain>This study evaluates the potential neuro-protective effects of delayed heliox treatment and its dose response effects in a rat transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model </plain></SENT>
<SENT sid="3" pm="."><plain>Adult male rats were subjected to 2-h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and then assigned to 1 of 4 inhaled gas exposure groups: I: 70%/30% nitrogen/oxygen (control); II: 70%/30% <z:chebi fb="64" ids="30217">helium</z:chebi>/oxygen administered immediately after occlusion; III: 70%/30% <z:chebi fb="64" ids="30217">helium</z:chebi>/oxygen administered after a 30-60 min delay; or, IV: 40%/30%/30% nitrogen/<z:chebi fb="64" ids="30217">helium</z:chebi>/oxygen administered immediately after occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>Outcome measurements included <z:mpath ids='MPATH_124'>infarct</z:mpath> size and neurological deficit score </plain></SENT>
<SENT sid="5" pm="."><plain>Mean <z:mpath ids='MPATH_124'>infarct</z:mpath> sizes from groups I to IV were 228, 35, 109, and 124 mmÂ³ respectively (p=0.012) </plain></SENT>
<SENT sid="6" pm="."><plain>Only group II had significantly smaller <z:mpath ids='MPATH_124'>infarct</z:mpath> size compared to the control group (p=0.008) </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, only Group II had a significantly lower neurological deficit score at 24h post <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> when compared to the control group (p&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Since heliox reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improved neurological deficit scores if initiated immediately after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, it may be a useful adjuvant to other <z:hpo ids='HP_0001297'>stroke</z:hpo> therapies </plain></SENT>
</text></document>